ALFA Filings
Every announcement, straight from the exchange
Every Senores Pharmaceuticals other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
9 announcements with these filters
Senores Pharmaceuticals reported no deviation in utilising the Rs 95 Crore raised via a preferential warrant issue for the quarter ended September 30, 2026. Audit Committee reviewed the statement and the Board took it on record.
Senores Pharmaceuticals appointed Talati and Talati LLP as Statutory Auditor for a 60-month term, effective 29 October 2026. The appointment was approved at the board meeting held the same day.
Senores Pharmaceuticals submitted its Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2026, as required by SEBI regulation 76.
Senores Pharmaceuticals Ltd submitted its shareholding pattern for the quarter ended 31 March 2026, in compliance with SEBI regulation 31(1)(b).
Senores Pharmaceuticals Ltd filed its quarterly shareholding pattern as mandated by SEBI regulations for the period ended June 30, 2026.
Senores Pharmaceuticals Ltd filed its quarterly shareholding pattern. The document details equity holdings across promoters, institutions, and public shareholders.
Senores Pharmaceuticals Limited submitted its Annual Secretarial Compliance Report for FY 2025-26. The auditor confirmed general compliance with SEBI regulations and secretarial standards.
Senores Pharmaceuticals Limited submitted its Reconciliation of Share Capital Audit Report for the quarter ended March 31, 2026. The report confirms a total issued capital of 4,60,53,588 shares, with 100% held in dematerialized form. It also notes a preferential allotment of 11,70,000 convertible equity warrants on March 28, 2026.
Senores Pharmaceuticals Limited submitted its quarterly certificate under Regulation 74(5) for the period ended March 31, 2026. The Registrar and Share Transfer Agent, MUFG Intime India, confirmed the processing of dematerialisation requests within prescribed timelines. This is a routine compliance filing with no material impact on operations.